Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CTX112 · 4 trials · 24 indications
Incidence of dose-limiting toxicities.
Incidence of dose-limiting toxicities.
Incidence of dose-limiting toxicities
| Arm | Type | Description |
|---|---|---|
| CTX112 | EXPERIMENTAL | Administered by IV infusion following lymphodepleting chemotherapy |
| CTX112 (zugo-cel) | EXPERIMENTAL | Administered by IV infusion following lymphodepleting chemotherapy |
| Name | Type | Description |
|---|---|---|
| CTX112 | BIOLOGICAL | CTX112 is a CD19-directed T-cell immunotherapy comprised of allogeneic T cells genetically modified ex vivo using CRISPR-Cas9 gene editing components |
Inclusion Criteria: 1. Age ≥18 years and \<70 years at screening. 2. Body weight \>40 kg. 3. Participants must voluntarily sign a written informed consent and be willing and able to comply with all trial requirements. Legal authorized representative, additional assent and witness may be used as app...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | - | Undisclosed |
CTX112 is an investigational CD19-targeted therapy being studied for B-cell lymphomas and other B-cell malignancies, as well as autoimmune diseases including systemic lupus erythematosus (SLE), warm autoimmune hemolytic anemia (WAIHA), and immune thrombocytopenia (ITP). It is in Phase 1 clinical development for these conditions.
CTX112 targets CD19, a protein found on the surface of B cells. By targeting CD19, CTX112 is designed to deplete or modify B cells involved in certain cancers and autoimmune diseases. This mechanism is being evaluated in clinical trials for B-cell malignancies and autoimmune conditions.
CTX112 is being developed by CRISPR Therapeutics AG, a biopharmaceutical company traded on NASDAQ under the ticker CRSP. The company is conducting Phase 1 clinical trials to evaluate the safety and efficacy of CTX112 in patients with B-cell malignancies and autoimmune diseases.
CTX112 is currently in Phase 1 clinical development. It is an investigational therapy, meaning it has not been approved by regulatory authorities. The drug is being studied in early-stage trials to assess its safety, tolerability, and preliminary efficacy in patients with B-cell cancers and autoimmune diseases.
CTX112 is being evaluated in three Phase 1 trials: NCT05643742 for relapsed or refractory B-cell malignancies, NCT06925542 for refractory autoimmune diseases including SLE, and NCT07549698 for relapsed or refractory hematologic autoimmune diseases such as WAIHA and ITP. All trials are currently recruiting participants.
CTX112 is a distinct investigational therapy targeting CD19, developed by CRISPR Therapeutics. It is not the same as other CD19-directed treatments, as it is a specific product candidate with its own clinical development program. No alternative names for CTX112 have been reported.